Cytokinetics reports Phase I, IIa results of cardiac myosin activator

The Phase I trial conducted in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients met the safety, tolerability, pharmacokinetics and pharmacodynamic effects of the drug.

Cytokinetics Biology and Therapeutics vice president Fady Malik said the two clinical trials have proven informative to the further advancement of the mechanism drug candidate which is now proceeding in a development program under their collaboration with Amgen.

Amgen executive medical director Scott Wasserman said these results form the foundation for the larger, international Phase IIb clinical trial of omecamtiv mecarbil which is currently enrolling heart failure patients.

"We are enthusiastic about the potential that omecamtiv mecarbil may represent for patients suffering from this illness and look forward to advance the development program in collaboration with Cytokinetics," Wasserman said.